These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36971102)

  • 1. A targeted literature review of health economic analyses of human papillomavirus vaccination from various countries.
    Segal HA; Rashid N
    Int J STD AIDS; 2023 Jul; 34(8):512-517. PubMed ID: 36971102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.
    Jit M; Demarteau N; Elbasha E; Ginsberg G; Kim J; Praditsitthikorn N; Sinanovic E; Hutubessy R
    BMC Med; 2011 May; 9():54. PubMed ID: 21569406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.
    Ben Hadj Yahia MB; Jouin-Bortolotti A; Dervaux B
    Clin Drug Investig; 2015 Aug; 35(8):471-85. PubMed ID: 26187455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis.
    Wahab MT; Tan RKJ; Cook AR; Prem K
    Vaccine; 2023 Mar; 41(12):1934-1942. PubMed ID: 36797100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
    Soe NN; Ong JJ; Ma X; Fairley CK; Latt PM; Jing J; Cheng F; Zhang L
    Hum Vaccin Immunother; 2018; 14(12):3010-3018. PubMed ID: 30024823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost effectiveness of human papillomavirus vaccines: a systematic review.
    Seto K; Marra F; Raymakers A; Marra CA
    Drugs; 2012 Mar; 72(5):715-43. PubMed ID: 22413761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
    Mvundura M; Slavkovsky R; Debellut F; Naddumba T; Bayeh A; Ndiaye C; Anena J; Vodicka E; Diop A; Gamage D; Musanabaganwa C; Tatkan G; Driwale A; Zelalem M; Badiane O; Ginige S; Hamilton E; Sibomana H; Lakew Y; Uwinkindi F; Dhufera A; Ampeire I; Kumar S; Lamontagne DS
    Vaccine; 2023 Nov; 41(49):7435-7443. PubMed ID: 37949752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
    Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
    BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns.
    Portnoy A; Campos NG; Sy S; Burger EA; Cohen J; Regan C; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):22-30. PubMed ID: 31666282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations.
    Ekwunife OI; O'Mahony JF; Gerber Grote A; Mosch C; Paeck T; Lhachimi SK
    Pharmacoeconomics; 2017 Jan; 35(1):65-82. PubMed ID: 27637758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
    Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
    Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
    Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.